Semaglutide Market Faces Slowdown with ₹100 Crore Excess Stock

The explosive growth in India's obesity and weight-loss therapy market has hit a sudden roadblock as sales momentum falters. After a massive surge following patent expirations, the semaglutide segment is now grappling with a significant inventory overhang that threatens profit margins for distributors.

The Inventory Overhang: A ₹100 Crore Challenge

Following an initial period of hyper-growth, the semaglutide therapy market has entered a period of sluggishness. Industry estimates suggest that stockists and wholesalers are currently sitting on an excess inventory valued at approximately ₹100 crore.

According to Rajiv Singhal, General Secretary of the All India Organisation of Chemists and Druggists (AIOCD), channel partners are currently holding between 50 to 60 days of stock. This is significantly higher than the standard industry norm of 30 to 45 days. Consequently, many wholesalers have hit a "pause" button on fresh procurement from pharmaceutical manufacturers, waiting for existing stocks to liquidate before placing new orders.

From Hyper-Growth to Moderation

The market's recent performance shows a stark contrast between April and May. In April, the ₹2,000-crore obesity therapy market experienced a massive boom, with value growth surging 50% month-on-month and volumes jumping by 88%. This frenzy was driven by the March 20 patent expiry of semaglutide, which allowed major Indian players like Sun Pharma, Dr. Reddy's, and Torrent to flood the market with cheaper generic alternatives.

However, data from market research firm Pharmarack reveals that this momentum lost steam in May. Month-on-month value growth decelerated to just 6%, while unit growth slowed to 12%. While the broader ₹2.5 lakh crore organized pharma retail market grew by 11%, the cooling of the GLP-1 segment stands out as a notable shift.

Regulatory Shifts and Competitive Landscape

Industry experts suggest that the sudden moderation in sales might not be purely a matter of supply and demand, but also a result of regulatory tightening. Recent government advisories and prescribing restrictions stipulate that GLP-1 therapies must only be prescribed by qualified specialists. This move aims to regulate the use of these drugs, which are primarily intended for type 2 diabetes and obesity management.

Despite the semaglutide slowdown, Eli Lilly’s Mounjaro (tirzepatide) continues to dominate the landscape. As a fellow GLP-1 receptor agonist, Mounjaro remained the largest selling therapy in the pharma market in May, with sales increasing by 12% to reach ₹136 crore.

Key Takeaways

  • Inventory Crisis: Stockists are holding 50–60 days of excess semaglutide stock, valued at roughly ₹100 crore, leading to a halt in fresh orders.
  • Growth Deceleration: After a 50% value surge in April following patent expiry, May saw growth plummet to just 6% month-on-month.
  • Regulatory Impact: Stricter guidelines requiring specialized prescriptions for GLP-1 therapies are believed to be a contributing factor to the cooling market.